Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
1.
Indian Journal of Critical Care Medicine ; 26:S108, 2022.
Article in English | EMBASE | ID: covidwho-2006399

ABSTRACT

Aim and background: Due to the resurgence of COVID cases many doctors, medical students, and nurses from varied backgrounds, many a time novice to COVID management are deployed in turn from time to time at different COVID care centers and hospitals across India, before they are properly trained and skilled for effective management of COVID and post COVID syndromes, as the disease is relatively new, leading to non-uniform management and documentation. COVID being a contagious disease with newer symptomatology and ongoing research outputs suggesting new guidelines from time to time, which sometimes are conflicting in nature for novice healthcare workers. For uniform and appropriate management to reduce morbidity and mortality, it mandates a unique and effective solution towards guided and error-free disease management, authentic high volume data capture for future research and to trace patient to post COVID condition in the community outside the hospital, virtual patient counselling cum relative visit, generation of the daily patient bulletin, simultaneous teleround of multiple units, and sharing patient's data across multiple specialities and investigation areas. Objective: To have all these above-mentioned facilities over one platform, we aim to test run a cloud-based dynamic mobile application based dedicated device, the C O V I D Device (Covid Operation Vital Information Delivery device) across many hospitals in India simultaneously for COVID and post COVID syndrome management and data retrieval for research. Materials and methods: Two institutes, namely IMS and SUM Hospital and ITER have collaborated to design a cloud-based device having recent COVID guidelines on the management of adult COVID patients. The software has been incorporated into a dedicated handheld device (tablet or android mobile phone), the COVID Device in a dynamic way (when new symptomatology surfaces and new research outcomes on management are published). The important modules pertaining to this COVID Device are Web-based application for Registration Desk and Device-based application for Doctor's Module/Care-givers Module and Patient's/Patient's relative's module. Results: In a pilot, we have successfully test run the COVID device on virtual patients and 2 actual patients in a secondary level COVID ICU and HDU to examine the different functionality of the cloud-based application, namely error-free and guided patient management without missing any point, daily patient relative's counselling and virtual patient visiting by relatives, generating daily patient bulletin, simultaneous tele round of multiple units, and sharing patient's data across multiple specialities and investigation areas and tracing patient to the community after discharge to enquire about post COVID condition and retrieval of data across all module and incorporation of new guideline in a dynamic way and checking the facilities for incorporating other modules namely pediatric module. Conclusion: COVID Device (Adult module) is a very effective tool for COVID and post COVID condition management and research. It has the potential to incorporate other modules namely obstetric, pediatric, and neonatal modules. If used across all hospital of India, it will be a real boost to digital health mission and centralized COVID data management and research in India.

2.
Chemistryselect ; 7(31), 2022.
Article in English | Web of Science | ID: covidwho-2003642

ABSTRACT

3,5-Di[(E)-arylidene]-1-[3-(4-methylpiperazin-1-yl)alkyl]piperidin-4-ones 7 a-k were synthesized through dehydrohalogenation of 1-(2-chloroacyl)piperidin-4-ones 5 a-k with N-methylpiperazine (6). High antiproliferation potencies were observed by most of the synthesized agents against both HCT116 (colon) and MCF7 (breast) cancer cell lines relative to the standard references (sunitinib and 5-fluorouracil). The synthesized agents are of dual activity against topoisomerases I and II alpha however, with higher efficacy against topoisomerase II alpha rather than topoisomerase I. Flow-cytometry cell cycle studies support the observed antiproliferation properties and exhibit the capability of 1-(2-chloroacetyl)-3,5-bis[(E)-4-chlorobenzylidene]piperidin-4-one (5 e) and 3,5-bis[(E)-4-bromobenzylidene]-1-[2-(4-methylpiperazin-1-yl)acetyl]piperidin-4-one (7 g) to arrest the HCT116 cell cycle progression at G1/S and G1 phases, respectively. Noticeable anti-SARS-CoV-2 properties were observed by many synthesized agents. 3,5-Bis[(E)-4-chlorobenzylidene]-1-[3-(4-methylpiperazin-1-yl)propanoyl]piperidin-4-one (7 f) is the most effective anti-SARS-CoV-2 synthesized with high SI. Applicability of the highly effective candidates synthesized as antitumor and anti-SARS-CoV-2 is due to the safety observations against normal (RPE1 and VERO-E6) cells. QSAR models validated internally and externally, support their possibility for optimizing more hits/leads.

3.
NeuroQuantology ; 20(8):4904-4912, 2022.
Article in English | EMBASE | ID: covidwho-1998067

ABSTRACT

In COVID-19 pandemic situations or in critical/emergency conditions patients experience a great problem because of the non-availability of doctors. A person in a medical emergency needs an immediate doctor to monitor and diagnose his/her medical problem and prescribe the medicine. In these types of critical conditions, there is a demand for some smart portable intensive care unit that can transmit the patient's vital parameters and provide this information to the doctor so that the patient gets lifesaving drugs as per the doctor’s prescription. This work proposed a low-cost and Internet of Things (IoT) based smart-portable intensive care unit (S-PICU) that is capable of transmitting the vital parameters of a patient to doctors’ mobile applications when the patient is in a remote location or transit because of a medical emergency. Patients in intensive care units (ICUs) with severe or life-threatening illnesses and injuries demand round-the-clock treatment, so this portable unit fulfils the medical requirement during emergency conditions. The android based mobile application fetches the patient’s data in real-time from the IoT cloud database system. A doctor can receive the patient’s data in digital and analog form on mobile and can easily set the drug infusion flow from their location. The proposed device helps the patient in critical/emergency conditions save a life because it can easily communicate with doctors through a smart mobile application and get prescribed drugs remotely. This device reduces doctors’ movement and better utilization of medical diagnoses. The automation feature of this device improves patient safety and features of this device improve the safety of patients and also the quality of medical treatment.

4.
2022 IEEE International Conference on Distributed Computing and Electrical Circuits and Electronics, ICDCECE 2022 ; 2022.
Article in English | Scopus | ID: covidwho-1932094

ABSTRACT

Identifying COVID-19 from other populations will help us better communicate health information in the future. Studying 836 students at ITM University and it is discovered that the covid-19 vaccination is accepted by 60.4% of students whereas just 13% of non-believers did, with a further 26% undecided. Many students at ITM University expressed an interest in learning more about the dangers of not being vaccinated, regardless of their personal reasons for not doing so. © 2022 IEEE.

5.
2nd International Conference on Biologically Inspired Techniques in Many Criteria Decision Making, BITMDM 2021 ; 271:131-140, 2022.
Article in English | Scopus | ID: covidwho-1919730

ABSTRACT

As the Indian auto-industry entered BS-VI era from April 2020, the value proposition of used cars grew stronger, as the new cars became expensive due to additional technology costs. Moreover, the unavailability of public transport and fear of infection force people toward self-mobility during the outbreak of Covid-19 pandemic. But, the surge in demand for used cars made some car sellers to take advantage from customers by listing higher prices than normal. In order to help consumers aware of market trends and prices for used cars, there comes the need to create a model that can predict the cost of used cars by taking into consideration about different features and prices of other cars present in the country. In this paper, we have used different machine learning algorithms such as k-nearest neighbor (KNN), random forest regression, decision tree, and light gradient boosting machine (LightGBM) which is able to predict the price of used cars based on different features specific to Indian buyers, and we have implemented the best model by comparing with other models to serve our cause. © 2022, The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

6.
5th International Conference on Smart Computing and Informatics, SCI 2021 ; 283:457-467, 2022.
Article in English | Scopus | ID: covidwho-1899062

ABSTRACT

The recent times we have seen that not taking proper measures like wearing mask or sanitization is the leading cause of the spread of “COVID-19”. Despite so many rules and regulations around the globe regarding proper sanitization and wearing of a mask, many people tend to ignore wearing of facemask when they are in public places. Although vaccines like covishield, covaxin, AstraZeneca, Pfizer-BioNTech, sputnik, etc. have been developed and the no of cases are decreasing in some countries to stop further transmit of virus it is still necessary to wear a mask in public places. Technology to monitor whether a person is wearing a mask in a public place or not is needed. One potential device like a CCTV camera can be used in this case. We came up with an algorithm “MaskYolo” which can be integrated with CCTV cameras that can detect if a person is wearing a mask or not using You Only Look Once (YOLO) algorithms. For our work, we used YOLOv4 and compared it to its sibling YOLOv4 Tiny. The best precision reached was 93.9 for YOLOv4 and 88.7 for YOLOv4 Tiny. Overall YOLOv4 stands out in all aspects for our model “MaskYolo”. Thus, we can use “MaskYolo” and build a device that detects if a person is wearing a mask or not. © 2022, The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

7.
Iranian Journal of Pharmaceutical Sciences ; 17(4):107-122, 2021.
Article in English | EMBASE | ID: covidwho-1897264

ABSTRACT

Rhus succedanea (Anacardiaceae) was used to treat multiple human afflictions. Literary works demonstrate that it has many biological activities. Today's research aims to recognize Rhus succedanea Phyto-derived anti-viral compounds against the main protease and spike protein of the viral agent of COVID-19 (SARS-CoV-2) gain insight into the molecular interactions. In the current study, ten molecules taken from R. succedanea are analyzed through docking, derived from the PubChem database. Docking experiments with Autodock vina and PyRx tools were conducted. AdmetSAR and DruLito servers were eventually used for drug-like prediction. Our research shows that the phytoconstituents from R. succedanea, namely, Amentoflavone, Rhoifolin, and Agathisflavone acts against SARS CoV-2 main protease with the binding affinity of-9.3,-8.6 and-8.4 Kcal/mol;Hinokiflavone Robustaflavone and Amentoflavone acts against the SARS-CoV-2 receptor-binding domain of spike protein with a binding affinity of-10.5,-10.4 and-10.1 Kcal/mol respectively. These phyto-compounds can use contemporary strategies to develop effective medicines from natural origins. The substances identified potential anti-viral as likely. However, In-vitro studies are even more necessary to assess their effectiveness versus SARS CoV-2.

9.
Journal of Heart and Lung Transplantation ; 41(4):S527-S527, 2022.
Article in English | Web of Science | ID: covidwho-1849264
12.
International Journal of Pharmaceutical and Clinical Research ; 14(4):194-200, 2022.
Article in English | EMBASE | ID: covidwho-1820613

ABSTRACT

Background: The SARS-CoV-2 (Covid-19) has significantly impacted the health of the people around the globe. Primary Total Hip arthroplasty (THA) and Total Knee arthroplasty (TKA) were significantly affected in the pandemic time. The canceled surgeries of THA and TKA were rescheduled as majority of the beds in the hospitals were occupied by COVID patients. Due to this, patients for such surgery accumulated and many patients faced serious health issues. In addition to THA and TKA, Covid-19 pandemic also significantly impacted Total Joint arthroplasty (TJA) volume. According to analysis, the annual volume of the TKA and THA for 2020 was around 128,000 and 66,000 respectively. Aim: To analyze the effect of COVID-19 on revision total knee and hip arthroplasty. Methods: For the study, the data was collected from the institutional registry for TJA and pending revisions for the TKA and THA patients. Approximately 465 inpatient beds between April 2019 and March 2020 considered for the study. Procedures were conducted for 12 months prior to the initial shutdown of elective surgery (April 19 – March 20). The percentage changes for urgent revisions for TJA were compared focusing on pre and post-Covid TKA and THA. Results: Two groups were defined as pre-Covid patients (n = 190) and post-Covid patients (n= 160). The mean age of the patient in pre-Covid group was 75.3 years (SD = 1.01) and post-Covid group was 68.9 years (SD = 11.52). For TKA revision, in pre-covid group, 33.3% of the patients had Aseptic loosening and 22.2% had Periprosthetic joint infection, and 16.6% required Urgent revision. On the other hand, in post-Covid group, 33.3% of the patients had Aseptic loosening and 21.2% had Periprosthetic joint infection, and 18.1% required Urgent revision. Post-Covid cases of THA were also increased as out of 94 patients, 15.9% required Urgent revision. There was no significant difference between the groups for TKA revision (p>0.05). Similarly, apart from Aseptic loosening (p<0.05), there was no significant difference between the groups for THA revision (p>0.05). Conclusion: It has been carried out that revision of TKA and THA decreased in health care system during Covid-19 pandemic compared to pre-Covid. The numbers of urgent cases were increased in both groups such as the numbers of urgent cases for THA were 15.9% and TKA was 18.1% post-Covid and these are creating the backlog for the care professionals to provide the better treatment and recovery of the patients.

13.
Indian Journal of Respiratory Care ; 11(1):52-58, 2022.
Article in English | Web of Science | ID: covidwho-1810701

ABSTRACT

Background: Atypical category of COVID-19 could not be differentiated from tuberculosis (TB) in high-resolution computed tomography (HRCT) of the chest because of similar imaging features. This study aims to distinguish between the HRCT features of TB and atypical COVID-19. Methodology: Interferon-gamma release assay (IGRA) was performed in all the 54 COVID-positive patients, showing atypical COVID features that are suspicious of TB on the HRCT chest. Atypical imaging features such as a tree in bud nodules, patchy consolidations, cavitation with surrounding consolidation, discrete nodules, mediastinal lymphadenopathy, and pleural effusion were analyzed in 50 IGRA-negative patients. Results: We found trees in bud nodules (93%) and consolidations (56%) involving predominantly lower lobes, i.e., superior and posterobasal segments. Discrete nodules and cavitation with surrounding consolidation were seen involving predominantly upper lobes (78 and 57% cases, respectively), i.e., apicoposterior and lingular segments of the left upper lobe. The maximum number (67%) of right paratracheal enlarged nodes and bilateral pleural effusions (71%) were found in IGRA-negative COVID-19 patients. Conclusions: It is not always possible to differentiate features of atypical COVID-19 from TB based on HRCT chest alone because of similar appearances and distribution of tree in bud nodules, consolidation, cavitation, and lymphadenopathy in HRCT chest. Since both bilateral and unilateral pleural effusions may be seen in TB, it is impossible to differentiate COVID-19 from TB based on pleural effusion. Therefore, exclusion of TB will need supportive, relevant laboratory investigations (Sputum acid fast bacilli, cartridge-based nucleic acid amplification test, and IGRA) for appropriate diagnosis and management.

14.
Egyptian Journal of Radiology and Nuclear Medicine ; 53(1), 2022.
Article in English | EMBASE | ID: covidwho-1799083

ABSTRACT

Background: The occurrence of invasive fungal infections in COVID-19 patients is on surge in countries like India. Several reports related to rhino-nasal-sinus mucormycosis in COVID patients have been published in recent times;however, very less has been reported about invasive pulmonary fungal infections caused mainly by mucor, aspergillus or invasive candida species. We aimed to present 6 sputum culture proved cases of invasive pulmonary fungal infection (four mucormycosis and two invasive candidiasis) in COVID patients, the clues for the diagnosis of fungal invasion as well as difficulties in diagnosing it due to superimposed COVID imaging features. Case presentation: The HRCT imaging features of the all 6 patients showed signs of fungal invasion in the form of cavities formation in the pre-existing reverse halo lesions or development of new irregular margined soft tissue attenuating growth within the pre-existing or in newly formed cavities. Five out of six patients were diabetics. Cavities in cases 1, 2, 3 and 4 of mucormycosis were aggressive and relatively larger and showed relatively faster progression into cavities in comparison with cases 5 and 6 of invasive candidiasis. Conclusion: In poorly managed diabetics or with other immunosuppressed conditions, invasive fungal infection (mucormycosis, invasive aspergillosis and invasive candidiasis) should be considered in the differential diagnosis of cavitary lung lesions.

15.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation ; 41(4):S525-S526, 2022.
Article in English | EuropePMC | ID: covidwho-1782207

ABSTRACT

Purpose Solid Organ Transplant recipients (SOT) are at higher risk of SARS-CoV-2 infection. Mortality rates reported between 13 to over 30% in SOT recipients. SARS‐CoV‐2 vaccination may help reduce the morbidity and mortality of COVID‐19 among SOT. There is paucity of literature of SARS-CoV-2 vaccination efficacy in lung transplantation recipients . The purpose of the study was 1) to evaluate SARS-CoV-2 vaccination efficacy & safety in lung transplantation recipients and 2) to assess the need for 3rd booster dose. Methods A retrospective study (from Jan 2021 till Oct 2021) of lung transplantation recipients receiving 2 doses of SARS-CoV-2 vaccination available in India i.e. ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant) or Whole-Virion Inactivated Vero Cell vaccine, was done to evaluate vaccination efficacy and safety. SARS-CoV-2 spike COVID antibodies levels were checked 4 weeks after 2nd dose of vaccination. Local and Systemic reactions to vaccination were noted Results 11 Bilateral lung transplantation recipients and 4 Combined Heart-Lung transplantation recipients received SARS-CoV-2 vaccination. Out of 15 recipients, 11 recipients received ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant) and 4 recipients received Whole-Virion Inactivated Vero Cell vaccine. 12 recipients developed mild pain at vaccination site, 2 recipients developed local tenderness and 1 recipient developed redness at vaccination site as part of local reaction . 5 recipients developed fever, 5 recipients experienced fatigue/bodypain, 2 recipients had vomiting, 2 recipients experienced headache & 1 recipient developed abdominal pain as part of systemic reactions. 8 (53.3%) out of 15 recipients developed significant SARS-CoV-2 spike antibodies level demonstrating vaccination efficacy. 7 (46.6%) recipients demonstrated lower SARS-CoV-2 antibodies titre (Less than cut off values) indicating no significant vaccination efficacy. 1 recipient developed vaccine breakthrough mild infection after 2nd dose. Conclusion Our experience has shown that SARS-CoV-2 vaccination efficacy was demonstrated in nearly 50 % of lung transplantation recipients. The study also showed safety of SARS-CoV-2 vaccines in such immunocompromised subset. However, for those recipients with no vaccination efficacy, utility of 3rd booster dose and at what interval needs more research.

16.
Journal of Heart & Lung Transplantation ; 41(4):S432-S432, 2022.
Article in English | Academic Search Complete | ID: covidwho-1783371

ABSTRACT

ECMO as a bridge, is a potential option in patients with severe COVID-19 who develop respiratory failure despite maximal conventional therapy. Heparin has been the standard anticoagulant, but is associated with bleeding and thrombocytopenia. Bivalirudin has been successfully used as an alternative in cases of heparin induced thrombocytopenia (HIT). We evaluated Bivalirudin as an anticoagulant in COVID-19 patients on ECMO who develop HIT or had persistent thrombocytopenia despite multiple platelet transfusions. After institutional clearance, we performed retrospective analysis of all the COVID-19 related ECMO managed in our centre between January to August 2021. Femoral vein to internal jugular vein ECMO was instituted in all these patients and anticoagulation targets were monitored daily as per institutional protocols. We compared incidence of ECMO circuit and oxygenator changes, post procedural bleeding and the number of blood products transfused between the Heparin and Bivalirudin group. Descriptive analysis was carried out by mean and standard deviation. The mean values were compared using student t-test and categorical outcomes using Chi square test. Total of 42 COVID-19 ARDS related ECMO were managed in our centre during the study period. 8 patients were switched to Bivalirudin, as 2 patients were diagnosed with HIT and 6 had persistent thrombocytopenia despite multiple platelet transfusions. In patients with HIT, the platelet count improved by 72 hours. The incidence of post tracheostomy and intercostal drain insertion bleed was statistically higher in Heparin group (p <0.05). Total number of packed cell transfusion was significantly less in Bivalirudin group but platelet transfusion was lower, though not statistically significant. The usage of fresh frozen plasma and cryoprecipitate were similar. The rates of ECMO oxygenator and circuit exchanges were comparable with mean duration of 13.5 days for change from the date of initiation. Bivalirudin is a feasible alternative anticoagulant in the COVID-19 ECMO with the benefit of lower rates of bleeding and consequent need for transfusion. Further large studies are needed to assess the efficacy and benefits of direct thrombin inhibitors as a practical and safe substitute to Heparin in these situations. [ FROM AUTHOR] Copyright of Journal of Heart & Lung Transplantation is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

17.
Journal of Heart & Lung Transplantation ; 41(4):S132-S133, 2022.
Article in English | Academic Search Complete | ID: covidwho-1783352

ABSTRACT

Severe COVID-19 ARDS related end stage lung fibrosis with irreversible changes is a newer indication for lung transplantation with acceptable survival rate. Airway complication post lung transplant is a major source of morbidity and mortality with incidence as high as 25 to 49 percent. Patients with end stage COVID-19 fibrosis are likely to be clinically deconditioned with long duration of extracorporeal oxygenator (ECMO) support, high burden of sepsis and prolonged respiratory support which may affect the airways post lung transplantation. This is a retrospective observational study after obtaining institutional ethical clearance. We reviewed electronic medical data of patients who underwent lung transplantation for post COVID-19 ARDS related fibrosis. We evaluated the incidence and type of airway complications and the various therapeutic interventions applied for its management. Between May 2020 and September 2021 our centre performed 23 bilateral lung transplants for end stage COVID-19 ARDS related fibrosis. 22 patients were on ECMO support with mean duration of 50.9 days before transplantation. All patients underwent lung transplantation with central Veno-Arterial ECMO support with mean organ ischaemia time of 360±154 minutes. The incidence of airway complication in our study group was 56%. We observed anastomotic narrowing in 3(13%), distal airway narrowing in 4(17%) and sloughing/coating of anastomotic site in 5(22%) patients. Nonspecific inflammatory polypi around the bronchial anastomotic site were noticed in 4(17%) and mild airway anastomotic dehiscence in 2 subjects. 8(34%) patients required serial bronchoscopy and balloon dilatation;2 among them mandated additional cautery usage. 2 cases underwent polypectomy, further 4 subjects needed bronchial stent placement. 5 (21%) recipients were discharged with Tracheostomy while rest were successfully decannulated in the ward. We observed a high incidence of airway complications in post lung transplant for COVID-19 ARDS related fibrosis. Early detection, timely management and serial follow up is of paramount importance in this subset of patients. [ FROM AUTHOR] Copyright of Journal of Heart & Lung Transplantation is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

18.
Indian Journal of Traditional Knowledge ; 21(1):157-167, 2022.
Article in English | Scopus | ID: covidwho-1777160

ABSTRACT

As a result of several ethnobotanical field visits in and around Alubari Jungle Busty of Darjeeling Himalaya from August 2012 till May 2019, mostly new ethnic uses of different plant parts including dosimetry of 24 wild plant species were documented. Documentation was based on oral interviews with experienced and elderly Nepalese people mainly in respect to immunity boosters and instant remedies against fevers including COVID-19. Some plant parts which were also used by the Nepalese of Alubari Jungle Busty as blood purifiers, lowering high blood pressure, energy provider during a long walk, diarrhoea, chronic piles, bronchitis, asthma, throat pain, cold and cough, were also documented. Present work also embodies botanically authenticated binomial names of documented wild plant species, vernacular names, knowledge informants, voucher information, live photographic documentation and study area map. © 2022, National Institute of Science Communication and Information Resources. All rights reserved.

SELECTION OF CITATIONS
SEARCH DETAIL